RUNX1 and fibrosis: These results underscore the potential therapeutic value of targeting EGR1, Gadd45b, or Runx1 to mitigate atrial fibrosis and inflammation, offering promising strategies for the treatment of cardiac remodeling‐associated pathologies, offering promising avenues for AF management.